Sensei Biotherapeutics Competitors

BioAtla (NASDAQ:BCAB) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Earnings & Valuation

This table compares BioAtla and Sensei Biotherapeutics' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current recommendations and price targets for BioAtla and Sensei Biotherapeutics, as provided by MarketBeat.com.

BioAtla presently has a consensus price target of $58.00, suggesting a potential upside of 22.49%. Sensei Biotherapeutics has a consensus price target of $29.50, suggesting a potential upside of 108.78%. Given Sensei Biotherapeutics' higher probable upside, analysts clearly believe Sensei Biotherapeutics is more favorable than BioAtla.

Profitability

This table compares BioAtla and Sensei Biotherapeutics' net margins, return on equity and return on assets.

Summary

Sensei Biotherapeutics beats BioAtla on 1 of the 1 factors compared between the two stocks.

Sensei Biotherapeutics (NASDAQ:SNSE) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Valuation and Earnings

This table compares Sensei Biotherapeutics and Immunocore's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Sensei Biotherapeutics and Immunocore, as provided by MarketBeat.com.

Sensei Biotherapeutics currently has a consensus price target of $29.50, suggesting a potential upside of 108.78%. Immunocore has a consensus price target of $54.3333, suggesting a potential upside of 53.18%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Sensei Biotherapeutics is more favorable than Immunocore.

Profitability

This table compares Sensei Biotherapeutics and Immunocore's net margins, return on equity and return on assets.

Summary

Sensei Biotherapeutics beats Immunocore on 3 of the 3 factors compared between the two stocks.

Sensei Biotherapeutics (NASDAQ:SNSE) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Valuation and Earnings

This table compares Sensei Biotherapeutics and Cullinan Oncology's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Sensei Biotherapeutics and Cullinan Oncology, as provided by MarketBeat.com.

Sensei Biotherapeutics currently has a consensus price target of $29.50, suggesting a potential upside of 108.78%. Cullinan Oncology has a consensus price target of $48.25, suggesting a potential upside of 49.38%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Sensei Biotherapeutics is more favorable than Cullinan Oncology.

Profitability

This table compares Sensei Biotherapeutics and Cullinan Oncology's net margins, return on equity and return on assets.

Summary

Sensei Biotherapeutics beats Cullinan Oncology on 3 of the 3 factors compared between the two stocks.

Sensei Biotherapeutics (NASDAQ:SNSE) and Cricut (NASDAQ:EWTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Valuation and Earnings

This table compares Sensei Biotherapeutics and Cricut's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Sensei Biotherapeutics and Cricut, as provided by MarketBeat.com.

Sensei Biotherapeutics currently has a consensus price target of $29.50, suggesting a potential upside of 108.78%. Given Sensei Biotherapeutics' higher probable upside, research analysts clearly believe Sensei Biotherapeutics is more favorable than Cricut.

Profitability

This table compares Sensei Biotherapeutics and Cricut's net margins, return on equity and return on assets.

Summary

Sensei Biotherapeutics beats Cricut on 2 of the 2 factors compared between the two stocks.

Kinnate Biopharma (NASDAQ:KNTE) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Profitability

This table compares Kinnate Biopharma and Sensei Biotherapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Kinnate Biopharma and Sensei Biotherapeutics, as provided by MarketBeat.

Kinnate Biopharma currently has a consensus target price of $52.00, suggesting a potential upside of 64.82%. Sensei Biotherapeutics has a consensus target price of $29.50, suggesting a potential upside of 108.78%. Given Sensei Biotherapeutics' higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Kinnate Biopharma.

Earnings and Valuation

This table compares Kinnate Biopharma and Sensei Biotherapeutics' revenue, earnings per share (EPS) and valuation.

Summary

Sensei Biotherapeutics beats Kinnate Biopharma on 1 of the 1 factors compared between the two stocks.

Sensei Biotherapeutics (NASDAQ:SNSE) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares Sensei Biotherapeutics and Silverback Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and target prices for Sensei Biotherapeutics and Silverback Therapeutics, as reported by MarketBeat.

Sensei Biotherapeutics presently has a consensus target price of $29.50, suggesting a potential upside of 108.78%. Silverback Therapeutics has a consensus target price of $50.25, suggesting a potential upside of 31.99%. Given Sensei Biotherapeutics' higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Silverback Therapeutics.

Valuation & Earnings

This table compares Sensei Biotherapeutics and Silverback Therapeutics' revenue, earnings per share and valuation.

Summary

Sensei Biotherapeutics beats Silverback Therapeutics on 1 of the 1 factors compared between the two stocks.